









Markets
/
Stocks
/
nasdaq-txmd
/

TherapeuticsMD Inc

TXMD

2.290USD

+0.100+4.57%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

26.50MMarket Cap

87.50P/E TTM



TherapeuticsMD Inc

2.290

+0.100+4.57%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of TherapeuticsMD Inc

Currency: USD Updated: 2026-02-06

Key Insights

TherapeuticsMD Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 118 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

TherapeuticsMD Inc's Score

Industry at a Glance

Industry Ranking

118 / 159

Overall Ranking

380 / 4521

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

TherapeuticsMD Inc Highlights

StrengthsRisks

TherapeuticsMD, Inc. is a pharmaceutical royalty company, which primarily collects royalties from its licensees. It receives royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. It granted a license to commercialize IMVEXXY, BIJUVA, and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands and assigned its exclusive license to commercialize ANNOVERA to Mayne Pharma. IMVEXXY (estradiol vaginal inserts) pharmaceutical product is for the treatment of moderate-to-severe dyspareunia. BIJUVA pharmaceutical product is a Food and Drug Administration (FDA)-approved bioidentical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate-to-severe vasomotor symptoms due to menopause in women with a uterus. ANNOVERA pharmaceutical product is a one-year ring-shaped contraceptive vaginal system (CVS).

Growing

The company is in a growing phase, with the latest annual income totaling USD 1.76M.

Overvalued

The company’s latest PE is 87.50, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 3.33M shares, decreasing 0.64% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 397.06K shares of this stock.

Analyst Rating

Based on 0 analysts

Current Rating

Target Price

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of TherapeuticsMD Inc is 9.21, ranking 15 out of 159 in the Pharmaceuticals industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 784.00K, representing a year-over-year increase of 43.33%, while its net profit experienced a year-over-year increase of 124.96%.

Score

Industry at a Glance

Previous score

9.21

Change



Financials

8.28

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

10.00

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.76

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

TherapeuticsMD Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of TherapeuticsMD Inc is 6.26, ranking 128 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is 87.50, which is 20.96% below the recent high of 105.85 and 148.26% above the recent low of -42.23.

Score

Industry at a Glance

Previous score

6.26

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 118/159

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

No earnings forecast score is currently available for TherapeuticsMD Inc. The Pharmaceuticals industry's average is 7.85.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of TherapeuticsMD Inc is 7.00, ranking 89 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 2.85 and the support level at 1.84, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.84

Change

0.16

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(4)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.082

Neutral

RSI(14)

54.000

Neutral

STOCH(KDJ)(9,3,3)

20.751

Neutral

ATR(14)

0.291

Low Volatility

CCI(14)

-51.166

Neutral

Williams %R

75.862

Sell

TRIX(12,20)

0.828

Sell

StochRSI(14)

66.226

Buy

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

2.264

Buy

MA10

2.311

Sell

MA20

2.310

Sell

MA50

1.952

Buy

MA100

1.601

Buy

MA200

1.403

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of TherapeuticsMD Inc is 3.00, ranking 93 out of 159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 28.78%, representing a quarter-over-quarter increase of 2.18%. The largest institutional shareholder is The Vanguard, holding a total of 397.06K shares, representing 3.43% of shares outstanding, with 3.96% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Rubric Capital Management LP

1.19M

Clearline Capital LP

635.22K

The Vanguard Group, Inc.

Star Investors

376.83K

-0.57%

Tejara Capital Ltd.

344.20K

-0.01%

Adar1 Capital Management LLC

209.21K

Morgan Stanley & Co. LLC

129.59K

-0.41%

BlackRock Institutional Trust Company, N.A.

116.13K

Geode Capital Management, L.L.C.

109.08K

Walker (Marlan D)

73.64K

Collins (Cooper C)

60.52K

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of TherapeuticsMD Inc is 1.71, ranking 146 out of 159 in the Pharmaceuticals industry. The company's beta value is 0.51. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.